Download Psychiatric Drug Discovery Book PDF

Download full Psychiatric Drug Discovery books PDF, EPUB, Tuebl, Textbook, Mobi or read online Psychiatric Drug Discovery anytime and anywhere on any device. Get free access to the library by create an account, fast download and ads free. We cannot guarantee that every book is in the library.

Drug Discovery for Psychiatric Disorders

Drug Discovery for Psychiatric Disorders
  • Author : Zoran Rankovic,Richard Hargreaves,Matilda Bingham
  • Publisher :Unknown
  • Release Date :2012-10-08
  • Total pages :678
  • ISBN : 9781849734943
GET BOOK HERE

Summary : The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism.

Animal and Translational Models for CNS Drug Discovery: Neurological disorders

Animal and Translational Models for CNS Drug Discovery: Neurological disorders
  • Author : Robert A. McArthur,Franco Borsini
  • Publisher :Unknown
  • Release Date :2008
  • Total pages :229
  • ISBN : OCLC:229026149
GET BOOK HERE

Summary :

Animal and Translational Models for CNS Drug Discovery: Neurological disorders

Animal and Translational Models for CNS Drug Discovery: Neurological disorders
  • Author : Robert A. McArthur,Franco Borsini
  • Publisher :Unknown
  • Release Date :2008
  • Total pages :229
  • ISBN : OCLC:229026149
GET BOOK HERE

Summary :

Mind Fixers: Psychiatry's Troubled Search for the Biology of Mental Illness

Mind Fixers: Psychiatry's Troubled Search for the Biology of Mental Illness
  • Author : Anne Harrington
  • Publisher :Unknown
  • Release Date :2019-04-16
  • Total pages :384
  • ISBN : 9781324001973
GET BOOK HERE

Summary : Mind Fixers tells the history of psychiatry’s quest to understand the biological basis of mental illness and asks where we need to go from here. In Mind Fixers, Anne Harrington, author of The Cure Within, explores psychiatry’s repeatedly frustrated struggle to understand mental disorder in biomedical terms. She shows how the stalling of early twentieth century efforts in this direction allowed Freudians and social scientists to insist, with some justification, that they had better ways of analyzing and fixing minds. But when the Freudians overreached, they drove psychiatry into a state of crisis that a new “biological revolution” was meant to alleviate. Harrington shows how little that biological revolution had to do with breakthroughs in science, and why the field has fallen into a state of crisis in our own time. Mind Fixers makes clear that psychiatry’s waxing and waning biological enthusiasms have been shaped not just by developments in the clinic and lab, but also by a surprising range of social factors, including immigration, warfare, grassroots activism, and assumptions about race and gender. Government programs designed to empty the state mental hospitals, acrid rivalries between different factions in the field, industry profit mongering, consumerism, and an uncritical media have all contributed to the story as well. In focusing particularly on the search for the biological roots of schizophrenia, depression, and bipolar disorder, Harrington underscores the high human stakes for the millions of people who have sought medical answers for their mental suffering. This is not just a story about doctors and scientists, but about countless ordinary people and their loved ones. A clear-eyed, evenhanded, and yet passionate tour de force, Mind Fixers recounts the past and present struggle to make mental illness a biological problem in order to lay the groundwork for creating a better future, both for those who suffer and for those whose job it is to care for them.

Drug Discovery for Nervous System Diseases

Drug Discovery for Nervous System Diseases
  • Author : Franz Hefti
  • Publisher :Unknown
  • Release Date :2005
  • Total pages :319
  • ISBN : UOM:39015060803650
GET BOOK HERE

Summary : The neurosciences have been an especially difficult field for drug discovery. Because of the huge complexity of the nervous system and poor understanding of most psychiatric and neurological diseases, most drugs currently available are the result of chance observations rather than a truly comprehensive approach. However, this situation has begun to change. Enormous progress in molecular biology has yielded breakthrough discoveries of the causes of nervous system diseases, opening the door for better-targeted and entirely novel therapies. Reflecting these recent advances, Drug Discovery for Nervous System Diseases presents the latest techniques and approaches for drug discovery, organizing them according to diseases rather than classes of drugs or drug targets, as past books have done. Written with optimistic anticipation of great progress still to come, this text provides both a guide to present realities and a look to future possibilities in this burgeoning field. Coverage in Drug Discovery for Nervous System Diseases includes: Fundamentals of drug discovery—receptors, target selection, and drug development Schizophrenia Depression Anxiety disorders Alzheimer's disease Parkinson's disease Ischemic stroke, brain, and spinal cord injury Other neurodegenerative diseases Sleep disorders Epilepsy Pain This practical handbook features a uniform presentation for each chapter, with a brief description of existing drugs leading to recent molecular biological and genetic findings, translational research and the interface to clinical trials, and finally an outlook on future drug targets. Rich illustrations—schematic diagrams and tables—provide a dynamic visual experience throughout the text. A unique and up-to-date guide to a field currently undergoing a major growth spurt, Drug Discovery for Nervous System Diseases offers both practitioners and advanced students an unparalleled resource.

The Book of Woe

The Book of Woe
  • Author : Gary Greenberg
  • Publisher :Unknown
  • Release Date :2013-05-02
  • Total pages :416
  • ISBN : 9781101621103
GET BOOK HERE

Summary : “Gary Greenberg has become the Dante of our psychiatric age, and the DSM-5 is his Inferno.” —Errol Morris Since its debut in 1952, the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders has set down the “official” view on what constitutes mental illness. Homosexuality, for instance, was a mental illness until 1973. Each revision has created controversy, but the DSM-5 has taken fire for encouraging doctors to diagnose more illnesses—and to prescribe sometimes unnecessary or harmful medications. Respected author and practicing psychotherapist Gary Greenberg embedded himself in the war that broke out over the fifth edition, and returned with an unsettling tale. Exposing the deeply flawed process behind the DSM-5’s compilation, The Book of Woe reveals how the manual turns suffering into a commodity—and made the APA its own biggest beneficiary.

Polypharmacology in Drug Discovery

Polypharmacology in Drug Discovery
  • Author : Jens-Uwe Peters
  • Publisher :Unknown
  • Release Date :2012-03-13
  • Total pages :510
  • ISBN : 9780470590904
GET BOOK HERE

Summary : "Covers the two-sided nature of polypharmacology--its contribution to adverse drug reactions and its benefit in certain therapeutic drug classes. Addresses the important topic of polypharmacology in drug discovery, a subject that has not been thoroughly covered outside of scattered journal articles Overviews state-of-the-art approaches and developments to help readers understand concepts and issues related to polypharmacology"--Provided by publisher.

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders
  • Author : Adeboye Adejare
  • Publisher :Unknown
  • Release Date :2016-09-20
  • Total pages :316
  • ISBN : 9780128028117
GET BOOK HERE

Summary : Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer’s Disease and illustrating the paradigm necessary to ensure future research and treatment success. The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer’s Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. It illustrates why these drugs tend to fail at the clinical stage, and examines Alzheimer’s Disease within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders. Provides a compilation of chemical considerations required in drug discovery for the treatment of neurodegenerative disorders Examines different classes of compounds currently being used in discovery and development stages Explores in vitro and in vivo models with respect to their ability to translate these models to human conditions Distills the most significant information across multiple areas of Alzheimer’s disease research to provide a single, comprehensive, and balanced resource

Blue Dreams

Blue Dreams
  • Author : Lauren Slater
  • Publisher :Unknown
  • Release Date :2018-02-20
  • Total pages :416
  • ISBN : 9780316370585
GET BOOK HERE

Summary : "Capacious and rigorous . . . Blue Dreams, like all good histories of medicine, reveals healing to be art as much as science." --Parul Sehgal, New York Times "Terrific." [email protected] "Ambitious...Slater's depictions of madness are terrifying and fascinating." --USA Today "A vivid and thought-provoking synthesis." --Harper's A groundbreaking and revelatory history of psychotropic drugs, from "a thoroughly exhilarating and entertaining writer" (Washington Post). Although one in five Americans now takes at least one psychotropic drug, the fact remains that nearly seventy years after doctors first began prescribing them, not even their creators understand exactly how or why these drugs work--or don't work--on what ails our brains. Blue Dreams offers the explosive story of the discovery and development of psychiatric medications, as well as the science and the people behind their invention, told by a riveting writer and psychologist who shares her own experience with the highs and lows of psychiatric drugs. Lauren Slater's revelatory account charts psychiatry's journey from its earliest drugs, Thorazine and lithium, up through Prozac and other major antidepressants of the present. Blue Dreams also chronicles experimental treatments involving Ecstasy, magic mushrooms, the most cutting-edge memory drugs, placebos, and even neural implants. In her thorough analysis of each treatment, Slater asks three fundamental questions: how was the drug born, how does it work (or fail to work), and what does it reveal about the ailments it is meant to treat? Fearlessly weaving her own intimate experiences into comprehensive and wide-ranging research, Slater narrates a personal history of psychiatry itself. In the process, her powerful and groundbreaking exploration casts modern psychiatry's ubiquitous wonder drugs in a new light, revealing their ability to heal us or hurt us, and proving an indispensable resource not only for those with a psychotropic prescription but for anyone who hopes to understand the limits of what we know about the human brain and the possibilities for future treatments.

21st Century Cures

21st Century Cures
  • Author : United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health
  • Publisher :Unknown
  • Release Date :2015
  • Total pages :165
  • ISBN : STANFORD:36105050679963
GET BOOK HERE

Summary :

Anatomy of an Epidemic

Anatomy of an Epidemic
  • Author : Robert Whitaker
  • Publisher :Unknown
  • Release Date :2010-04-13
  • Total pages :416
  • ISBN : 0307452433
GET BOOK HERE

Summary : Now with bonus material, including a new foreword and afterword with updated research In this astonishing and startling book, award-winning science and history writer Robert Whitaker investigates a medical mystery: Why has the number of disabled mentally ill in the United States tripled over the past two decades? Every day, 1,100 adults and children are added to the government disability rolls because they have become newly disabled by mental illness, with this epidemic spreading most rapidly among our nation’s children. What is going on? Anatomy of an Epidemic challenges readers to think through that question themselves. First, Whitaker investigates what is known today about the biological causes of mental disorders. Do psychiatric medications fix “chemical imbalances” in the brain, or do they, in fact, create them? Researchers spent decades studying that question, and by the late 1980s, they had their answer. Readers will be startled—and dismayed—to discover what was reported in the scientific journals. Then comes the scientific query at the heart of this book: During the past fifty years, when investigators looked at how psychiatric drugs affected long-term outcomes, what did they find? Did they discover that the drugs help people stay well? Function better? Enjoy good physical health? Or did they find that these medications, for some paradoxical reason, increase the likelihood that people will become chronically ill, less able to function well, more prone to physical illness? This is the first book to look at the merits of psychiatric medications through the prism of long-term results. Are long-term recovery rates higher for medicated or unmedicated schizophrenia patients? Does taking an antidepressant decrease or increase the risk that a depressed person will become disabled by the disorder? Do bipolar patients fare better today than they did forty years ago, or much worse? When the National Institute of Mental Health (NIMH) studied the long-term outcomes of children with ADHD, did they determine that stimulants provide any benefit? By the end of this review of the outcomes literature, readers are certain to have a haunting question of their own: Why have the results from these long-term studies—all of which point to the same startling conclusion—been kept from the public? In this compelling history, Whitaker also tells the personal stories of children and adults swept up in this epidemic. Finally, he reports on innovative programs of psychiatric care in Europe and the United States that are producing good long-term outcomes. Our nation has been hit by an epidemic of disabling mental illness, and yet, as Anatomy of an Epidemic reveals, the medical blueprints for curbing that epidemic have already been drawn up.

Seminars in Clinical Psychopharmacology

Seminars in Clinical Psychopharmacology
  • Author : Peter M. Haddad,David J. Nutt
  • Publisher :Unknown
  • Release Date :2020
  • Total pages :229
  • ISBN : 191162346X
GET BOOK HERE

Summary : "The 2nd edition of this book was edited by David King and published in 2004. Since then there have been major advances in psychopharmacology in terms of new medications coming to the market, increased understanding of the mechanisms of drug action and new data on the efficacy, tolerability, safety and clinical effectiveness of a range of medications. Partly as a result, clinical guidelines for many psychiatric disorders have altered. As such, a new edition of this textbook was essential and we were delighted when the College approached us to edit the 3rd edition. This was a major endeavor that was only possible with the commitment and expertise of the authors"--

Anti-Obesity Drug Discovery and Development

Anti-Obesity Drug Discovery and Development
  • Author : Atta-ur- Rahman,M. Iqbal Choudhary
  • Publisher :Unknown
  • Release Date :2011-07-07
  • Total pages :293
  • ISBN : 9781608051632
GET BOOK HERE

Summary : "Obesity is a complex health problem, caused by a number of factors such as excessive food intake, lack of physical activity, genetic predisposition, endocrine disorders, medications and psychiatric illnesses. Onset of obesity in both the developing and th"

Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders

Animal and Translational Models for CNS Drug Discovery: Reward Deficit Disorders
  • Author : Robert A. McArthur,Franco Borsini
  • Publisher :Unknown
  • Release Date :2009-02-24
  • Total pages :432
  • ISBN : 9780080920405
GET BOOK HERE

Summary : Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. Reward Deficit Disorders also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process Critical evaluation of animal and translational models improving transition from drug discovery and clinical development Emphasizes what results mean to the overall drug discovery process Explores issues in clinical trial design and conductance in each therapeutic area Neurological Disorders is available for purchase individually.

Personalized Psychiatry

Personalized Psychiatry
  • Author : Bernhard Baune
  • Publisher :Unknown
  • Release Date :2019-10-16
  • Total pages :604
  • ISBN : 9780128131770
GET BOOK HERE

Summary : Personalized Psychiatry presents the first book to explore this novel field of biological psychiatry that covers both basic science research and its translational applications. The book conceptualizes personalized psychiatry and provides state-of-the-art knowledge on biological and neuroscience methodologies, all while integrating clinical phenomenology relevant to personalized psychiatry and discussing important principles and potential models. It is essential reading for advanced students and neuroscience and psychiatry researchers who are investigating the prevention and treatment of mental disorders. Combines neurobiology with basic science methodologies in genomics, epigenomics and transcriptomics Demonstrates how the statistical modeling of interacting biological and clinical information could transform the future of psychiatry Addresses fundamental questions and requirements for personalized psychiatry from a basic research and translational perspective

Successful Drug Discovery

Successful Drug Discovery
  • Author : János Fischer,Christian Klein,Wayne E. Childers
  • Publisher :Unknown
  • Release Date :2019-07-20
  • Total pages :272
  • ISBN : 9783527814718
GET BOOK HERE

Summary : Provides unique insider insight into the current drug development process, and what it takes to achieve success In this fourth volume in the series, inventors and primary developers of drugs that made it to the market continue telling the story of the drugs? discovery and development, and discuss the sometimes twisted route from the first drug candidate molecule to the final marketed one. Beginning with a general section addressing overarching topics for drug discovery, the book offers seven chapters that feature selected case studies describing recently introduced drugs or drug classes. These include small molecule drugs as well as biopharmaceuticals and range across different therapeutic fields. Together, they provide a representative cross-section of the present-day drug development effort. Successful Drug Discovery: Volume 4 covers trends in peptide-based drug discovery and the physicochemical properties of recently approved oral drugs. The section on drug class studies looks at antibody-drug conjugates and the discovery, evolution, and therapeutic potential of dopamine partial agonists. Featured case studies examine the discovery of Etelcalcetide for the treatment of secondary hyper-parathyroidism in patients with chronic kidney disease; the development of Lenvatinib Mesylate; the discovery and development of Venetoclax; and more. -Focuses on recently introduced drugs that have not been featured in any textbooks or general references, including Ocrelizumab, a new generation of anti-CD-20 mAb for the treatment of multiple sclerosis, and Venetoclax, a selective antagonist of BCL-2 -Features personal experiences of successful drug developers from industry and academia -Endorsed and supported by the International Union of Pure and Applied Chemistry (IUPAC) Successful Drug Discovery: Volume 4 provides a fascinating and informative look into the process of drug discovery and would be a great reference for those in the pharmaceutical industry, organic and pharmaceutical chemists, and lecturers in pharmacy.

Lithium: A Doctor, a Drug, and a Breakthrough

Lithium: A Doctor, a Drug, and a Breakthrough
  • Author : Walter A. Brown
  • Publisher :Unknown
  • Release Date :2019-08-13
  • Total pages :288
  • ISBN : 9781631492006
GET BOOK HERE

Summary : The remarkable untold story of a miracle drug, the forgotten pioneer who discovered it, and the fight to bring lithium to the masses. The DNA double helix, penicillin, the X-ray, insulin—these are routinely cited as some of the most important medical discoveries of the twentieth century. And yet, the 1949 discovery of lithium as a cure for bipolar disorder is perhaps one of the most important—yet largely unsung—breakthroughs of the modern era. In Lithium, Walter Brown, a practicing psychiatrist and professor at Brown, reveals two unlikely success stories: that of John Cade, the physician whose discovery would come to save an untold number of lives and launch a pharmacological revolution, and that of a miraculous metal rescued from decades of stigmatization. From insulin comas and lobotomy to incarceration to exile, Brown chronicles the troubling history of the diagnosis and (often ineffective) treatment of bipolar disorder through the centuries, before the publication of a groundbreaking research paper in 1949. Cade’s “Lithium Salts in the Treatment of Psychotic Excitement” described, for the first time, lithium’s astonishing efficacy at both treating and preventing the recurrence of manic-depressive episodes, and would eventually transform the lives of patients, pharmaceutical researchers, and practicing physicians worldwide. And yet, as Brown shows, it would be decades before lithium would overcome widespread stigmatization as a dangerous substance, and the resistance from the pharmaceutical industry, which had little incentive to promote a naturally occurring drug that could not be patented. With a vivid portrait of the story’s unlikely hero, John Cade, Brown also describes a devoted naturalist who, unlike many modern medical researchers, did not benefit from prestigious research training or big funding sources (Cade’s “laboratory” was the unused pantry of an isolated mental hospital). As Brown shows, however, these humble conditions were the secret to his historic success: Cade was free to follow his own restless curiosity, rather than answer to an external funding source. As Lithium makes tragically clear, medical research—at least in America—has transformed in such a way that serendipitous discoveries like Cade’s are unlikely to occur ever again. Recently described by the New York Times as the “Cinderella” of psychiatric drugs, lithium has saved countless of lives and billions of dollars in healthcare costs. In this revelatory biography of a drug and the man who fought for its discovery, Brown crafts a captivating picture of modern medical history—revealing just how close we came to passing over this extraordinary cure.

Polypharmacy in Psychiatry Practice, Volume I

Polypharmacy in Psychiatry Practice, Volume I
  • Author : Michael S Ritsner
  • Publisher :Unknown
  • Release Date :2013-02-15
  • Total pages :287
  • ISBN : 9789400758056
GET BOOK HERE

Summary : Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume set is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.

Genomics, Circuits, and Pathways in Clinical Neuropsychiatry

Genomics, Circuits, and Pathways in Clinical Neuropsychiatry
  • Author : Thomas Lehner,Bruce L. Miller,Matthew W. State
  • Publisher :Unknown
  • Release Date :2016-06-07
  • Total pages :796
  • ISBN : 9780128005309
GET BOOK HERE

Summary : This foundational work comprehensively examines the current state of the genetics, genomics and brain circuitry of psychiatric and neurological disorders. It consolidates discoveries of specific genes and genomic regions associated with these conditions, the genetic and anatomic architecture of these syndromes, and addresses how recent advances in genomics are leading to a reappraisal of the biology underlying clinical neuroscience. In doing so, it critically examines the promise and limitations of these discoveries toward treatment, and to the interdisciplinary nature of understanding brain and behavior. Coverage includes new discoveries regarding autism, epilepsy, intellectual disability, dementias, movement disorders, language impairment, disorders of attention, schizophrenia, and bipolar disorder. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry focuses on key concepts, challenges, findings, and methods in genetics, genomics, molecular pathways, brain circuitry, and related neurobiology of neurologic and psychiatric disorders. Provides interdisciplinary appeal in psychiatry, neurology, neuroscience, and genetics Identifies key concepts, methods, and findings Includes coverage of multiple disorders from autism to schizophrenia Reviews specific genes associated with disorders Discusses the genetic architecture of these syndromes Explains how recent findings are influencing the understanding of biology Clarifies the promise of these findings for future treatment

Blaming the Brain

Blaming the Brain
  • Author : Elliot Valenstein
  • Publisher :Unknown
  • Release Date :2002-02-01
  • Total pages :304
  • ISBN : 9780743237871
GET BOOK HERE

Summary : In Blaming the Brain Elliott Valenstein exposes the many weaknesses inherent in the scientific arguments supporting the widely accepted theory that biochemical imbalances are the main cause of mental illness. He lays bare the commercial motives of drug companies and their huge stake in expanding their markets. This provocative book will force patients, practitioners, and prescribers alike to rethink the causes of mental illness and the methods by which we treat it.

New Frontiers in Psychotropic Drug Research

New Frontiers in Psychotropic Drug Research
  • Author : Stuart Fielding,Richard C. Effland
  • Publisher :Unknown
  • Release Date :1979
  • Total pages :262
  • ISBN : UOM:39015003225714
GET BOOK HERE

Summary :